{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:49:59Z","timestamp":1781272199041,"version":"3.54.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Canadian Institutes of Health Research Project Grant","award":["PJT 178214"],"award-info":[{"award-number":["PJT 178214"]}]},{"name":"Canadian Institutes of Health Research Project Grant","award":["PJT 178214"],"award-info":[{"award-number":["PJT 178214"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"DOI":"10.1038\/s41540-025-00618-7","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:46:15Z","timestamp":1765615575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Challenges and opportunities for oncology drug repurposing informed by synthetic lethality"],"prefix":"10.1038","volume":"11","author":[{"given":"Michael","family":"Vermeulen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Babak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"618_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrg.2017.47","volume":"18","author":"NJ O\u2019Neil","year":"2017","unstructured":"O\u2019Neil, N. J., Bailey, M. L. & Hieter, P. Synthetic lethality and cancer. Nat. Rev. Genet 18, 613\u2013623 (2017).","journal-title":"Nat. Rev. Genet"},{"key":"618_CR2","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1158\/2159-8290.CD-20-1503","volume":"11","author":"J Setton","year":"2021","unstructured":"Setton, J. et al. Synthetic lethality in cancer therapeutics: the next generation. Cancer Discov. 11, 1626\u20131635 (2021).","journal-title":"Cancer Discov."},{"key":"618_CR3","doi-asserted-by":"crossref","unstructured":"Rose, M., Burgess, J. T., O\u2019Byrne, K., Richard, D. J., & Bolderson, E. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front. Cell Dev. Biol. 8, https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2020.564601 (2020).","DOI":"10.3389\/fcell.2020.564601"},{"key":"618_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00763-x","author":"R Arafeh","year":"2024","unstructured":"Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C. & Vazquez, F. The present and future of the cancer dependency map. Nat. Rev. Cancer https:\/\/doi.org\/10.1038\/s41568-024-00763-x (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"618_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35378-z","volume":"13","author":"S Srivatsa","year":"2022","unstructured":"Srivatsa, S. et al. Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens. Nat. Commun. 13, 7748 (2022).","journal-title":"Nat. Commun."},{"key":"618_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34161-4","volume":"13","author":"M Markowska","year":"2023","unstructured":"Markowska, M. et al. Synthetic lethality prediction in DNA damage repair, chromatin remodeling and the cell cycle using multi-omics data from cell lines and patients. Sci. Rep. 13, 7049 (2023).","journal-title":"Sci. Rep."},{"key":"618_CR7","doi-asserted-by":"publisher","first-page":"e202302268","DOI":"10.26508\/lsa.202302268","volume":"7","author":"M Karimpour","year":"2024","unstructured":"Karimpour, M., Totonchi, M., Behmanesh, M. & Montazeri, H. Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens. Life Sci. Alliance 7, e202302268 (2024).","journal-title":"Life Sci. Alliance"},{"key":"618_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-023-01446-6","volume":"16","author":"J Rosenski","year":"2023","unstructured":"Rosenski, J., Shifman, S. & Kaplan, T. Predicting gene knockout effects from expression data. BMC Med. Genomics 16, 26 (2023).","journal-title":"BMC Med. Genomics"},{"key":"618_CR9","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20199405","volume":"16","author":"E Gon\u00e7alves","year":"2020","unstructured":"Gon\u00e7alves, E. et al. Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens. Mol. Syst. Biol. 16, e9405 (2020).","journal-title":"Mol. Syst. Biol."},{"key":"618_CR10","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.58925","volume":"9","author":"CJ Lord","year":"2020","unstructured":"Lord, C. J., Quinn, N. & Ryan, C. J. Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions. eLife 9, e58925 (2020).","journal-title":"eLife"},{"key":"618_CR11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576.e16 (2017).","journal-title":"Cell"},{"key":"618_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello, S. M. et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nat. Cancer 1, 235\u2013248 (2020).","journal-title":"Nat. Cancer"},{"key":"618_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01405-8","volume":"20","author":"S Benfatto","year":"2021","unstructured":"Benfatto, S. et al. Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality. Mol. Cancer 20, 111 (2021).","journal-title":"Mol. Cancer"},{"key":"618_CR14","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.21.959627","author":"JM Dempster","year":"2020","unstructured":"Dempster, J. M. et al. Gene expression has more power for predicting in vitro cancer cell vulnerabilities than genomics. Cancer Biol. https:\/\/doi.org\/10.1101\/2020.02.21.959627 (2020).","journal-title":"Cancer Biol."},{"key":"618_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108066","volume":"170","author":"Y Dou","year":"2024","unstructured":"Dou, Y. et al. CSSLdb: Discovery of cancer-specific synthetic lethal interactions based on machine learning and statistic inference. Comput. Biol. Med. 170, 108066 (2024).","journal-title":"Comput. Biol. Med."},{"key":"618_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67846-1","volume":"10","author":"A Bazaga","year":"2020","unstructured":"Bazaga, A., Leggate, D. & Weisser, H. Genome-wide investigation of gene-cancer associations for the prediction of novel therapeutic targets in oncology. Sci. Rep. 10, 10787 (2020).","journal-title":"Sci. Rep."},{"key":"618_CR17","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-024-00789-y","volume":"5","author":"X Shi","year":"2024","unstructured":"Shi, X. et al. Building a translational cancer dependency map for The Cancer Genome Atlas. Nat Cancer. 5, 1176\u20131194 (2024).","journal-title":"Nat Cancer."},{"key":"618_CR18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/s42256-022-00541-0","volume":"4","author":"D He","year":"2022","unstructured":"He, D., Liu, Q., Wu, Y. & Xie, L. A context-aware deconfounding autoencoder for robust prediction of personalized clinical drug response from cell-line compound screening. Nat. Mach. Intell. 4, 879\u2013892 (2022).","journal-title":"Nat. Mach. Intell."},{"key":"618_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh1275","volume":"7","author":"Y-C Chiu","year":"2021","unstructured":"Chiu, Y.-C. et al. Predicting and characterizing a cancer dependency map of tumors with deep learning. Sci. Adv. 7, eabh1275 (2021).","journal-title":"Sci. Adv."},{"key":"618_CR20","doi-asserted-by":"publisher","first-page":"lqaf052","DOI":"10.1093\/nargab\/lqaf052","volume":"7","author":"Z Cohen","year":"2025","unstructured":"Cohen, Z. et al. SLAYER: a computational framework for identifying synthetic lethal interactions through integrated analysis of cancer dependencies. NAR Genom. Bioinform. 7, lqaf052 (2025).","journal-title":"NAR Genom. Bioinform."},{"key":"618_CR21","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1016\/j.csbj.2021.08.001","volume":"19","author":"T Fedrizzi","year":"2021","unstructured":"Fedrizzi, T. et al. Fast mutual exclusivity algorithm nominates potential synthetic lethal gene pairs through brute force matrix product computations. Comput. Struct. Biotechnol. J. 19, 4394\u20134403 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"618_CR22","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1109\/JBHI.2024.3354776","volume":"28","author":"H Liany","year":"2024","unstructured":"Liany, H. et al. ASTER: a method to predict clinically relevant synthetic lethal genetic interactions. IEEE J. Biomed. Health Inf. 28, 1785\u20131796 (2024).","journal-title":"IEEE J. Biomed. Health Inf."},{"key":"618_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-015-0086-1","volume":"10","author":"S Srihari","year":"2015","unstructured":"Srihari, S., Singla, J., Wong, L. & Ragan, M. A. Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer. Biol. Direct 10, 57 (2015).","journal-title":"Biol. Direct"},{"key":"618_CR24","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013D961 (2013).","journal-title":"Nucleic Acids Res."},{"key":"618_CR25","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/s41467-025-56827-5","volume":"16","author":"F Carli","year":"2025","unstructured":"Carli, F. et al. Learning and actioning general principles of cancer cell drug sensitivity. Nat Commun. 16, 1654 (2025).","journal-title":"Nat Commun."},{"key":"618_CR26","doi-asserted-by":"publisher","first-page":"e0295629","DOI":"10.1371\/journal.pone.0295629","volume":"19","author":"B Baek","year":"2024","unstructured":"Baek, B. et al. Integrated drug response prediction models pinpoint repurposed drugs with effectiveness against rhabdomyosarcoma. PLoS ONE 19, e0295629 (2024).","journal-title":"PLoS ONE"},{"key":"618_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03182-1","volume":"21","author":"S Pellecchia","year":"2023","unstructured":"Pellecchia, S., Viscido, G., Franchini, M. & Gambardella, G. Predicting drug response from single-cell expression profiles of tumours. BMC Med. 21, 476 (2023).","journal-title":"BMC Med."},{"key":"618_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-15-0189","volume":"14","author":"A Goodspeed","year":"2016","unstructured":"Goodspeed, A., Heiser, L. M., Gray, J. W. & Costello, J. C. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol. Cancer Res. 14, 3\u201313 (2016).","journal-title":"Mol. Cancer Res."},{"key":"618_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1541-7786.MCR-07-0280","volume":"6","author":"A Li","year":"2008","unstructured":"Li, A. et al. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol. Cancer Res. 6, 21\u201330 (2008).","journal-title":"Mol. Cancer Res."},{"key":"618_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba1862","volume":"6","author":"M Salvadores","year":"2020","unstructured":"Salvadores, M., Fuster-Tormo, F. & Supek, F. Matching cell lines with cancer type and subtype of origin via mutational, epigenomic, and transcriptomic patterns. Sci. Adv. 6, eaba1862 (2020).","journal-title":"Sci. Adv."},{"key":"618_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","volume":"173","author":"MH Bailey","year":"2018","unstructured":"Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371\u2013385.e18 (2018).","journal-title":"Cell"},{"key":"618_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"PJ Campbell","year":"2020","unstructured":"Campbell, P. J. et al. Pan-cancer analysis of whole genomes. Nature 578, 82\u201393 (2020).","journal-title":"Nature"},{"key":"618_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00830-0","volume":"13","author":"J Nulsen","year":"2021","unstructured":"Nulsen, J., Misetic, H., Yau, C. & Ciccarelli, F. D. Pan-cancer detection of driver genes at the single-patient resolution. Genome Med. 13, 12 (2021).","journal-title":"Genome Med."},{"key":"618_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-023-00492-8","volume":"8","author":"P Truesdell","year":"2024","unstructured":"Truesdell, P. et al. Pharmacogenomic discovery of genetically targeted cancer therapies optimized against clinical outcomes. npj Precis. Oncol. 8, 1\u201313 (2024).","journal-title":"npj Precis. Oncol."},{"key":"618_CR35","doi-asserted-by":"publisher","first-page":"62091","DOI":"10.18632\/oncotarget.11388","volume":"7","author":"J Zemanova","year":"2016","unstructured":"Zemanova, J. et al. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. Oncotarget 7, 62091\u201362106 (2016).","journal-title":"Oncotarget"},{"key":"618_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14098","volume":"8","author":"V Tagal","year":"2017","unstructured":"Tagal, V. et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat. Commun. 8, 14098 (2017).","journal-title":"Nat. Commun."},{"key":"618_CR37","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.chembiol.2023.08.002","volume":"30","author":"H Ji","year":"2023","unstructured":"Ji, H. et al. Target deconvolution with matrix-augmented pooling strategy reveals cell-specific drug-protein interactions. Cell Chem. Biol. 30, 1478\u20131487.e7 (2023).","journal-title":"Cell Chem. Biol."},{"key":"618_CR38","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","volume":"55","author":"X Xu","year":"2023","unstructured":"Xu, X. et al. Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Exp. Mol. Med. 55, 1357\u20131370 (2023).","journal-title":"Exp. Mol. Med."},{"key":"618_CR39","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/1873-3468.14950","volume":"598","author":"SK Wooller","year":"2024","unstructured":"Wooller, S. K., Pearl, L. H. & Pearl, F. M. G. Identifying actionable synthetically lethal cancer gene pairs using mutual exclusivity. FEBS Lett. 598, 2028\u20132039 (2024).","journal-title":"FEBS Lett."},{"key":"618_CR40","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.molcel.2020.04.027","volume":"78","author":"S Shu","year":"2020","unstructured":"Shu, S. et al. Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer. Mol. Cell 78, 1096\u20131113.e8 (2020).","journal-title":"Mol. Cell"},{"key":"618_CR41","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41417-023-00706-y","volume":"31","author":"H Geng","year":"2024","unstructured":"Geng, H. et al. Leveraging synthetic lethality to uncover potential therapeutic target in gastric cancer. Cancer Gene Ther. 31, 334\u2013348 (2024).","journal-title":"Cancer Gene Ther."},{"key":"618_CR42","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1038\/s41388-018-0300-6","volume":"37","author":"K Berns","year":"2018","unstructured":"Berns, K. et al. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene 37, 4611\u20134625 (2018).","journal-title":"Oncogene"},{"key":"618_CR43","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200219","volume":"218","author":"AKH Loe","year":"2021","unstructured":"Loe, A. K. H. et al. Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy. J. Exp. Med. 218, e20200219 (2021).","journal-title":"J. Exp. Med."},{"key":"618_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40\u201351 (2014).","journal-title":"Nat. Biotechnol."},{"key":"618_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrd.2016.238","volume":"16","author":"C Fellmann","year":"2017","unstructured":"Fellmann, C., Gowen, B. G., Lin, P.-C., Doudna, J. A. & Corn, J. E. Cornerstones of CRISPR\u2013Cas in drug discovery and therapy. Nat. Rev. Drug Discov. 16, 89\u2013100 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"618_CR46","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s42003-021-02352-2","volume":"4","author":"Y Xia","year":"2021","unstructured":"Xia, Y. et al. Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform. Commun. Biol. 4, 834 (2021).","journal-title":"Commun. Biol."},{"key":"618_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14620-6","volume":"11","author":"PC DeWeirdt","year":"2020","unstructured":"DeWeirdt, P. C. et al. Genetic screens in isogenic mammalian cell lines without single cell cloning. Nat. Commun. 11, 752 (2020).","journal-title":"Nat. Commun."},{"key":"618_CR48","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.24179","volume":"6","author":"A Lin","year":"2017","unstructured":"Lin, A., Giuliano, C. J., Sayles, N. M. & Sheltzer, J. M. CRISPR\/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. eLife 6, e24179 (2017).","journal-title":"eLife"},{"key":"618_CR49","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature14580","volume":"524","author":"A Rossi","year":"2015","unstructured":"Rossi, A. et al. Genetic compensation induced by deleterious mutations but not gene knockdowns. Nature 524, 230\u2013233 (2015).","journal-title":"Nature"},{"key":"618_CR50","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41586-019-1064-z","volume":"568","author":"MA El-Brolosy","year":"2019","unstructured":"El-Brolosy, M. A. et al. Genetic compensation triggered by mutant mRNA degradation. Nature 568, 193\u2013197 (2019).","journal-title":"Nature"},{"key":"618_CR51","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR\u2013Cas9 genome editing induces a p53-mediated DNA damage response. Nat. Med. 24, 927\u2013930 (2018).","journal-title":"Nat. Med."},{"key":"618_CR52","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067\u20131073 (2010).","journal-title":"Nature"},{"key":"618_CR53","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031\u20131037 (2001).","journal-title":"N. Engl. J. Med."},{"key":"618_CR54","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/COC.0000000000000023","volume":"39","author":"MR Green","year":"2016","unstructured":"Green, M. R., Newton, M. D. & Fancher, K. M. Off-target effects of BCR-ABL and JAK2 inhibitors. Am. J. Clin. Oncol. 39, 76\u201384 (2016).","journal-title":"Am. J. Clin. Oncol."},{"key":"618_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw8412","volume":"11","author":"A Lin","year":"2019","unstructured":"Lin, A. et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11, eaaw8412 (2019).","journal-title":"Sci. Transl. Med."},{"key":"618_CR56","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","volume":"163","author":"T Hart","year":"2015","unstructured":"Hart, T. et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163, 1515\u20131526 (2015).","journal-title":"Cell"},{"key":"618_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 15, 81\u201394 (2018).","journal-title":"Nat Rev Clin Oncol."},{"key":"618_CR58","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/d41586-021-00182-0","volume":"589","author":"JS Boehm","year":"2021","unstructured":"Boehm, J. S. et al. Cancer research needs a better map. Nature 589, 514\u2013516 (2021).","journal-title":"Nature"},{"key":"618_CR59","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ccell.2019.08.002","volume":"36","author":"JM Hess","year":"2019","unstructured":"Hess, J. M. et al. Passenger hotspot mutations in cancer. Cancer Cell 36, 288\u2013301.e14 (2019).","journal-title":"Cancer Cell"}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00618-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:02:20Z","timestamp":1766581340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00618-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["618"],"URL":"https:\/\/doi.org\/10.1038\/s41540-025-00618-7","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.B. is the founder and CSO of Leapfrog Bio Inc. and is the majority shareholder. All authors declare no non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}